7.57
0.35 (4.85%)
| Previous Close | 7.22 |
| Open | 7.26 |
| Volume | 854,560 |
| Avg. Volume (3M) | 892,253 |
| Market Cap | 500,001,856 |
| Price / Earnings (Forward) | 17.01 |
| Price / Sales | 1.65 |
| Price / Book | 53.71 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2026 |
| Profit Margin | -20.40% |
| Operating Margin (TTM) | -19.00% |
| Diluted EPS (TTM) | -0.890 |
| Quarterly Revenue Growth (YOY) | 15.50% |
| Total Debt/Equity (MRQ) | 2,353.84% |
| Current Ratio (MRQ) | 2.34 |
| Operating Cash Flow (TTM) | -23.02 M |
| Levered Free Cash Flow (TTM) | -9.39 M |
| Return on Assets (TTM) | -9.36% |
| Return on Equity (TTM) | -949.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Evolus, Inc. Common Stock | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -1.67 |
Select this tab to load the latest available analysis.
|
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 5.46% |
| % Held by Institutions | 85.15% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |